Skip to main content

Advertisement

Table 3 Summary of clinical chemistry data; mean (SD), N = 8

From: Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations

Variable (reference range and units)a Day Group 1 (sham) Group 2 (2 mg/kg) Group 3 (6 mg/kg) Group 4 (10 mg/kg) P-value2
Treatment
Alkaline phosphatase (1–114 U/L) Pretest 89.3 (25.9) 101.5 (21.9) 86.4 (11.5) 94.4 (16.1) 0.8687
30 76.8 (28.7) 82.9 (16.8) 70.0 (10.6) 79.3 (15.0)
91 47.9 (17.6) 53.5 (14.2) 45.1 (10.9) 50.6 (8.5)
181 36.6 (17.1) 41.8 (15.3) 36.1 (6.0) 42.1 (8.6)
Aspartate aminotransferase (28–60 U/L) Pretest 35.1 (5.3) 35.5 (5.3) 38.1 (8.3) 36.1 (9.5) 0.7180
30 31.1 (6.8) 30.3 (6.2) 30.1 (4.0) 30.4 (3.8)
91 30.4 (5.5) 34.8 (3.8) 31.3 (5.4) 26.8 (3.5)
181 27.9 (8.6) 27.1 (5.3) 27.8 (4.7) 28.8 (3.7)
Alanine aminotransferase (10–109 U/L) Pretest 27.6 (5.0) 28.8 (4.1) 28.4 (7.8) 28.6 (7.2) 0.8099
30 30.6 (7.1) 29.4 (5.6) 32.6 (5.8) 29.3 (3.5)
91 30.5 (6.6) 36.0 (10.1) 31.9 (5.1) 34.1 (12.9)
181 32.3 (12.8) 29.0 (7.0) 33.6 (9.5) 37.6 (12.8)
Creatine kinase (52–368 U/L) Pretest 312.1 (153.0) 261.8 (98.7) 278.8 (52.5) 324.4 (228.5) 0.7749
30 216.5 (57.9) 186.8 (56.5) 182.1 (26.6) 211.4 (40.8)
91 185.8 (38.8) 248.3 (153.8) 182.3 (44.3) 163.8 (41.6)
181 197.1 (81.3) 174.4 (55.3) 180.9 (59.0) 179.1 (45.8)
Urea nitrogen (8–28 mg/dL) Pretest 11.0 (2.6) 11.5 (1.6) 11.4 (2.1) 11.1 (1.9) 0.5554
30 13.8 (2.8) 13.3 (1.6) 13.4 (2.3) 13.8 (1.8)
91 15.3 (1.9) 15.0 (2.8) 14.1 (2.9) 13.0 (2.4)
181 15.1 (2.4) 15.5 (2.5) 14.3 (2.8) 15.6 (1.8)
Creatinine (0.5–1.7 mg/dL) Pretest 0.59 (0.08) 0.60 (0.05) 0.59 (0.04) 0.58 (0.07) 0.8214
30 0.70 (0.14) 0.69 (0.06) 0.66 (0.07) 0.68 (0.07)
91 0.73 (0.10) 0.74 (0.07) 0.69 (0.08) 0.69 (0.10)
181 0.76 (0.14) 0.74 (0.09) 0.74 (0.05) 0.74 (0.07)
Total Protein (5.4–7.5 g/dL) Pretest 5.83 (0.20) 5.56 (0.17) 5.75 (0.31) 5.68 (0.27) 0.6166
30 5.90 (0.26) 5.61 (0.11) 5.76 (0.36) 5.75 (0.25)
91 5.69 (0.16) 5.46 (0.15) 5.55 (0.40) 5.60 (0.23)
181 6.46 (0.14) 6.19 (0.14) 6.23 (0.38) 6.25 (0.30)
Albumin (2.9–3.9 g/dL) Pretest 3.34 (0.16) 3.18 (0.12) 3.20 (0.15) 3.21 (0.10) 0.0631
30 3.24 (0.17) 3.08 (0.15) 3.09 (0.16) 3.19 (0.16)
91 3.48 (0.15) 3.35 (0.12) 3.24 (0.19) 3.36 (0.11)
181 3.64 (0.12) 3.31 (0.12) 3.31 (0.22) 3.45 (0.13)
Direct bilirubin (0.0–0.3 mg/dL) Pretest (−) (−) (−) (−) 0.4098
30 0.00 (0.00) 0.01 (0.04) 0.00 (0.00) 0.04 (0.05)
91 0.04 (0.05) 0.00 (0.00) 0.03 (0.05) 0.00 (0.00)
181 0.01 (0.04) 0.00 (0.00) 0.01 (0.04) 0.01 (0.04)
Cholesterol (135–278 mg/dL) Pretest 164.3 (30.1) 145.8 (24.3) 155.5 (22.5) 158.6 (23.1) 0.1893
30 156.6 (26.6) 136.5 (19.2) 142.4 (14.7) 146.0 (18.0)
91 153.1 (41.3) 131.1 (18.6) 133.9 (12.1) 147.4 (24.8)
181 194.4 (54.2) 186.1 (55.0) 177.1 (37.6) 158.0 (30.4)
Calcium (9.1–11.7 mg/dL) Pretest 11.01 (0.33) 10.73 (0.21) 10.86 (0.26) 10.91 (0.26) 0.0423
30 11.03 (0.28) 10.93 (0.18) 10.85 (0.26) 10.99 (0.27)
91 10.54 (0.15) 10.46 (0.09) 10.30 (0.20) 10.46 (0.31)
181 10.86 (0.37) 10.74 (0.11) 10.69 (0.18) 10.88 (0.23)
  1. Footnote:
  2. a These reference ranges are to be used for information only and the pretest values collected before the dosing period during acclimatization should be used for interpretation in the context of this study
  3. 2 P-values in bold denote significance
  4. (−) Direct bilirubin was not analyzed for the pretest interval due to a protocol deviation